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Abstract: Gastric cancer remains a significant health burden worldwide. Most of these 
  malignancies are diagnosed at an advanced stage and are associated with a grim   prognosis. 
  Complete removal of macroscopic and microscopic tumor masses along with regional 
lymphnodes (R0 surgical resection) represents the treatment of choice in localized, nonmeta-
static gastric cancer. Chemotherapy, either alone as a perioperative treatment, or in combination 
with radiation therapy in an adjuvant setting, improves the clinical outcome for patients with 
resectable tumors. In patients suffering from metastatic disease, chemotherapy and the so-called 
targeted therapies play a major role in improving survival and quality of life compared with best 
supportive care. The emergence of new drugs as well as new administration schedules allow 
physicians to obtain an objective response of up to 60% and, since the utilization of targeted 
therapies, overall survival has reached 14 months. In order to situate the standard of care and 
the latest developments in gastric malignancies better, the pertinent English literature, including 
major Phase III randomized studies and meta-analyses, has been reviewed.
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Introduction
Despite major efforts to detect upper gastrointestinal malignancies as early as pos-
sible, gastric cancer remains one of the leading causes of cancer-related death. It also 
represents the fourth most commonly diagnosed tumor worldwide, with approximately 
one million newly detected cancers per year.1,2 Small lesions are usually asymptomatic 
and detected fortuitously or in screening programs, explaining why approximately 
65% of patients are diagnosed in stages III–IV , 85% with positive lymphonodular 
involvement and 30% already with liver metastases.3 An additional causative factor 
explaining the grim prognosis comes from tumor biology and the change in the distri-
bution of gastric cancer from the antrum and body to the proximal stomach. Proximal 
lesions are in fact biologically more aggressive and have a worse prognosis (stage for 
stage) than distal gastric cancers.4 Less than 50% of patients are suitable for surgery, 
which is the only curative modality. According to certain criteria, early gastric cancers 
limited to the mucosa or submucosa are indicated for endoscopic mucosal resection, 
while gastrectomy is indicated for more advanced tumors, or as a salvage therapy. 
The questions of resection type, extent of lymph node dissection, and indication for 
splenectomy could be debated.
For many years, there were very few reported improvements in the efficacy of 
chemotherapy for advanced gastric cancer, with median overall survival   remaining 
below 1 year. The emergence of new agents, such as targeted therapies, allows Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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  physicians to increase survival to around 14 months, for the 
first time. However, choice of the optimal chemotherapy 
regimen should take into account the high toxicity of most 
of the chemotherapy regimens used in this setting and the 
importance of assessing which patients will benefit the most 
from treatment, in order to extend the length of life with 
preservation of quality of life.
This review summarizes the emergent treatments for 
gastric cancer, based on the standard of care published in the 
literature based on randomized controlled studies and meta-
analyses, in order to help physicians in their clinical practice. 
A systematic search of all the English language literature 
regarding gastric cancer treatment was performed, using 
a MEDLINE search for the period January 2005 to March 
2011. Future drug developments are also discussed.
Chemotherapy with curative  
intent: neoadjuvant and adjuvant  
treatments
Perioperative therapy
Chemotherapy and radiation therapy play a major role in the 
management of resectable gastric tumors. The   combination 
of different chemotherapeutic drugs in the perioperative 
setting has been demonstrated to be more effective in 
resectable gastric cancer than surgery alone. Cunningham 
et al in a randomized Phase III study comparing sur-
gery alone vs perioperative chemotherapy (epirubicin 
50 mg/m² + cisplatin 60 mg/m² on day 1 combined with 
continuous intravenous infusion of 5-FU 200 mg/m²/day for 
21 days [ECF]) plus surgery, demonstrated a statistically 
significant improvement in progression-free survival and 
overall survival in the chemotherapy group (Table 1). Inter-
estingly, a noteworthy downstaging effect of chemotherapy 
was also demonstrated in T1 and T2 tumors at surgery in 
favor of chemotherapy of 51.7% vs 36.8%.5 Despite the 
fact that more than one-third of the patients did not start 
adjuvant chemotherapy, patients assigned to perioperative 
chemotherapy had a significant survival advantage over 
those who underwent surgery alone, questioning the role 
of adjuvant ECF in that   setting. The perioperative strategy 
was also supported by data from the Federation Nationale 
des Centres de Lutte Contre le Cancer ACCORD07-FFCD 
9703 trial of perioperative 5-FU + cisplatin (two or three 
preoperative cycles of cisplatin 100 mg/m² on day 1, and 
a continuous intravenous infusion of 5-FU 800 mg/m² 
for 5 consecutive days every 28 days), and three or four 
postoperative cycles of the same regimen for patients with 
resectable adenocarcinoma of the stomach, esophagogastric 
junction, or lower esophagus. The reported 5-year overall 
survival was significantly higher in the chemotherapy 
group. A better 5-year disease-free survival and a higher 
R0 resection rate (significantly increased from 73% to 
84% by neoadjuvant chemotherapy with P = 0.04) were 
also observed (Table 1).6 Based upon these two studies, we 
can recommend perioperative chemotherapy in resectable 
gastric tumors, regardless of stage.
Neoadjuvant therapy
Results with neoadjuvant-only chemotherapy are   disappointing. 
Schumacher et al recently reported the results of a random-
ized Phase III trial comparing surgery alone with neoadjuvant 
chemotherapy (cisplatin 50 mg/m² days 1-15-29, folinic acid 
500 mg/m² and continuous infusion 5-FU 2 g/m² over 24 hours 
on days 1-8-15-22-29-36) plus surgery. The R0 resection 
rate was significantly increased by the neoadjuvant chemo-
therapy (81.9% vs 66.7%, P = 0.036), but this study failed 
to demonstrate any survival advantage in the chemotherapy 
group (Table 1).7 This trial was considered to be statistically 
under powered to detect a potential survival difference. It is 
of interest that more than 50% of patients received reduced or 
incomplete chemotherapy cycles, which could partly explain 
the negative results of the study. Other accurate data regarding 
neoadjuvant therapy are lacking in the literature.
Adjuvant therapy
Chemotherapy has been widely studied in Japan in the 
adjuvant setting, especially using the new fluoropyrimidine 
oral compounds, uracil-tegafur and S-1. In the earliest 
study, patients were randomized to receive uracil-tegafur 
vs observation. The 5-year overall survival was 73% in the 
control arm and 86% in the treatment arm (P = 0.017).8 
The study was dedicated to a specific tumor population 
(pT2pN1-2 adenocarcinoma), rendering the results rather 
robust (Table 1).
A second positive study was published by Sakuramoto 
et al in a more heterogeneous group of patients, including all 
tumor stages (except T1 lesions). The 3-year overall survival 
rate was higher in the S-1 group (Table 1). Relapse-free 
survival at 3 years was also ameliorated by administration 
of S-1 (P , 0.001).9 Based on these results, S-1 has become 
a standard option in Japan for adjuvant chemotherapy. 
Numerous randomized clinical trials have compared surgery 
alone with adjuvant chemotherapy, but definitive evidence is 
lacking. Many of these trials have had limited sample sizes, 
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published meta-analysis of 17 randomized controlled trials 
of adjuvant chemotherapy in gastric cancer demonstrated a 
modest but statistically significant benefit associated with 
fluorouracil based adjuvant chemotherapy after curative 
resection of gastric cancers, in terms of overall survival 
(hazards ratio [HR]: 0.82, 95% confidence interval [CI]: 
0.76–0.90; P , 0.001) and disease-free survival (HR: 0.82, 
95% CI: 0.75–0.90; P , 0.001) compared with surgery 
alone.10 This approach might therefore become an alterna-
tive in this setting.
Although widely criticized for the quality of the surgery, 
the Intergroup 0116 trial included a total of 556 patients 
with completely resected adenocarcinoma of the stomach or 
esophagogastric junction. They were randomized to receive 
either adjuvant 5-FU + leucovorin in combination with 
radiation therapy or observation. The median overall survival 
was significantly improved in the adjuvant arm (Table 1). 
Although better in terms of efficacy, the chemoradiation arm 
was associated with significant toxicity (three toxic deaths 
[1%], 41% grade 3 toxicity, and 32% grade 4 toxicity).11 
However, this regimen remains an option in patients for whom 
preoperative chemotherapy has not been given and when the 
tumor is at high risk of recurrence.
Palliative setting
While the use of chemotherapy is indisputable in a pallia-
tive setting, treatment decisions should take into account 
the possible high toxicity commonly observed in most 
  chemotherapy regimens utilized, and balance that toxicity 
against the benefit to patients. To help clinicians determine 
good candidates for palliative chemotherapy, Chau et al 
recently demonstrated that not all patients will benefit 
from such treatment. They identified independent prog-
nostic factors reducing   survival in treated patients, such as 
a performance status of 2,   presence of liver and/or perito-
neal involvement, and alkaline   phosphatase . 100 U/L.12 
Patients with none of these factors benefited from chemo-
therapy, with a median overall survival of 11.8 months, 
while patients having three of four   prognostic factors had 
a worse prognosis, with a median survival of 4.1 months. 
This observation may help physicians to select patients for 
whom chemotherapy might be beneficial.
Chemotherapy compared with best 
supportive care
The majority of the patients with gastric cancer present 
with advanced disease at diagnosis, rendering the prognosis 
extremely poor. In these patients, palliative treatments are 
given with the intention of improving quality of life and 
prolonging survival. The role of palliative chemotherapy in 
improving survival compared with best supportive care is 
no longer controversial, because the results of three stud-
ies published 20 years ago demonstrated a clear advantage 
for patients receiving chemotherapy, in terms of improving 
either quality of life or survival.13–15 Furthermore, data from 
eleven randomized trials that included approximately 1500 
patients from several European and US centers were exam-
ined by Wagner et al in a meta-analysis published in 2006. 
In the majority of the studies, patients in the control arms 
received 5-FU-based chemotherapy, administered either as a 
bolus or as a continuous infusion. Examining the individual 
studies, nine of eleven did not show significant differences in 
survival between the two groups. However, the meta-analysis 
found a statistically significant advantage in favor of combi-
nation compared with single-agent chemotherapy (HR: 0.83, 
95% CI: 0.74–0.93; P , 0.001).16 Quality of life was only 
studied in one of the eleven trials and demonstrated a real 
benefit for treated patients, confirming the results of the 
previous published trials.16
Which chemotherapy for first-line 
therapy?
Many drugs have been studied in gastric cancer either in 
combination or as monotherapy. Over the years, we have 
learnt from the literature that combination therapies are 
more effective in terms of response rate, overall survival, 
and quality of life than single drugs, leading to single-agent 
therapy not being prescribed nowadays in advanced gastric 
cancer.16 We have also observed over the years that two of 
the oldest drugs, cisplatin and 5-FU, are still worthwhile, 
and are considered as the cornerstone of many combination 
therapies.
Physicians have now isolated several chemotherapeu-
tic regimens which can still be used for advanced gastric 
malignancies (Table 2). Dual therapy of cisplatin + 5-FU 
was compared with 5-FU + adriamycin + methotrexate and 
etoposide + leucovorin + 5-FU in a randomized Phase III study 
published by Vanhoefer et al in 2000. Although the combina-
tion did not show any survival advantage, the dual therapy 
was associated with a significant better response rate and 
toxicity profile than the two other regimens, showing that dual 
therapy could be better than multiple drug therapy.17 Waters 
et al published the final results of a randomized Phase III trial 
comparing ECF with 5-FU + adriamycin +   methotrexate. 
ECF showed a survival advantage compared with 5-FU + 
adriamycin + methotrexate, with a better overall response Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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rate and toxicity profile (Table 2).18 This combination is still 
in use in many countries, but has been progressively replaced 
by new combination therapies of docetaxel + cisplatin + 5-FU, 
although no head-to-head comparisons have been reported in 
the literature   demonstrating that   docetaxel + cisplatin + 5-FU 
is better than ECF. The only relevant data published in the 
  literature comes from a   randomized Phase II trial studying three 
chemotherapy regimens, ie, docetaxel +   cisplatin + 5-FU, doc-
etaxel +   cisplatin, and ECF. The authors showed a trend favor-
ing the   docetaxel + cisplatin + 5-FU combination in terms of 
response rate and median time to progression compared with 
ECF. However, despite its apparent lower efficacy, the ECF 
regimen was better tolerated, with patients experiencing less 
toxicity and   having a better quality of life.19 It is of interest 
to note that this randomized Phase II study was not designed 
to compare the three regimens with each other.
Docetaxel 75 mg/m² + cisplatin 75 mg/m² + 5-FU 
750 mg/m² on days 1–5 every 3 weeks has recently become 
the standard of care in metastatic gastric tumors, and 
improved response rate, progression-free survival, and over-
all survival compared with cisplatin + 5-FU as the control 
treatment in a randomized Phase III trial published by Van 
Cutsem et al (Table 2).20 One should keep in mind that the 
percentage of patients receiving subsequent lines of treat-
ment was lower for the docetaxel + cisplatin + 5-FU arm 
than for the cisplatin + 5-FU arm (32% vs 41%), rendering 
the survival results rather robust. Despite high hematological 
toxicity (grade 3–4 neutropenia in 82%, complicated neu-
tropenia in 29%), the authors demonstrated that quality of 
life was better preserved in the docetaxel + cisplatin + 5-FU 
arm.21 Physicians have tried to improve the toxicity profile of 
the standard docetaxel + cisplatin + 5-FU regimen by either 
using a different administration schedule or modifying the 
combination itself.22–24 Data from 95 patients treated with 
weekly docetaxel 20 mg/m² + cisplatin 20 mg/m² + 5-FU 
350 mg/m² for 6 consecutive weeks followed by a 2-week 
break were retrospectively collected from 2002 to 2006 at 
The University of Texas MD Anderson Center. A response 
rate of 34% (95% CI: 24–45) and a median overall sur-
vival of 8.9 months (95% CI: 7.7–10.8) were observed.22 
Hematological toxicity was tolerable. However, caution is 
advised when interpreting the results regarding retrospective 
analysis of the data. In a randomized Phase II trial, Tebbutt 
et al studied a weekly regimen of docetaxel 30 mg/m² on 
Table 2 Results of major Phase III studies using combination therapies in first-line therapy for metastatic gastric cancer
n Regimen RR (%) TTF P value Median  
PFS
P value Median  
OS
P value
waters et al18 130/126 FAMTX/eCF 21/46 – – – – 6.1/8.7 0.0005
vanhoefer et al17 134/132/133 CF/eLF/FAMTX 20/9/12 – – 4.1/3.3/3.3 NS 7.2/7.2.6.9 NS
van Cutsem et al20 224/221 CF/DCF 25/37 – – 3.7/5.6 ,0.001 8.6/9.2 0.02
Cunningham et al27 263/245/ 
250/244
eCF/eOF/ 
eCX/eOX
41/42/46/48 – – 6.2/6.5/6.7/7 NS 9.9/9.3/9.9/ 
11.2
0.02
Dank et al30 172/165 iF/CF 31.8/25.8 4/3.4 0.0018 7.4/7.6 NS 9/8.7 NS
Guimbaud et al31 174/175 eCX/ FOLFiRi 4/5 0.008 5.3/5.75 – 9.5/9.7 NS
Boku et al32 234/235/234 5-FU/CP/S-1 9/38/28 – – – – 10.8/12.3/ 
11.4
NS
Kang et al34 160/156 XP/FP 46/32 – – 5.6/5 NS 10.5/9.3 NS
Koizumi et al35 148/150 CS-1/S-1 54/31 – – 6/4 ,0.0001 13/11 0.04
Ajani et al36 527/526 CS-1/CF 29.1/31.9 – – 4.8/5.5 NS 8.6/7.9 NS
Abbreviations: n, number of patients; NS, not significant; RR, response rate; TTF, time to treatment failure; PFS, progression free survival; OS, overall survival; F, fluorouracil; 
5-FU, infusional 5-fluorouracil; A, adriamycin; MTX, methotrexate; E, epirubicin; C, cisplatin; L, leucovorin; D, docetaxel; O, oxaliplatin; X, capecitabine; I or IRI, irinotecan.
Table 1 Neoadjuvant and adjuvant therapy in locally advanced gastric cancer
n Setting Arm DFS (%) P value OS (%) P value
Cunningham et al5 250/253 Perioperative POC/S 30/18 ,0.001 36.3/29.5 =0.009
Ychou et al6 113/111 Perioperative POC/S 34/19 =0.003 38/24 =0.021
Schuhmacher et al7 72/72 Neoadjuvant NC + S/S – NS – NS
Nakajima et al8 95/95 Adjuvant S + UFT/S – – 86/73 0.017
Sakuramoto et al9 529/530 Adjuvant S + S-1/S – – 80.1/70.1 0.003
MacDonald et al11 281/275 Adjuvant S + CR/S 48/31 ,0.001 50/41 0.005
Abbreviations: DFS, disease-free survival; OS, overall survival; POC, perioperative chemotherapy; S, surgery; NC, neoadjuvant; CR, chemoradiotherapy.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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days 1 and 8 +cisplatin 60 mg/m² on day 1 + 5-FU 200 mg/
m²/day continuously, every 3 weeks, and a combination 
of docetaxel 30 mg/m² on days 1 and 8 + capecitabine 
1600 mg/m²/day on days 1–14, every 3 weeks. Response 
rates were 47% and 26% in the weekly docetaxel + cis-
platin + 5-FU and the docetaxel + capecitabine arm, 
respectively, whereas a better median overall survival was 
observed in the weekly docetaxel + cisplatin + 5-FU arm 
(11.2 months and 10.1 months, respectively). Both groups 
showed a favorable toxicity profile, especially in terms of 
hematological toxicity.23 Subsequently, Li et al compared 
the combination of weekly docetaxel 36 mg/m² +cisplatin 
30 mg/m² on days 1 and 8 with uracil-tegafur 300 mg/m²/
day on days 1–14 every 3 weeks in 45 chemo-naïve patients 
suffering from metastatic gastric cancer. The results were 
rather interesting because the response rate reached 58%, 
with a median overall survival of 13.9 months, which is 
rarely observed in this setting. The toxicity profile was also 
tolerable.24 These data suggest that ameliorating the toxicity 
profile of the docetaxel + cisplatin + 5-FU regimen is feasible 
without jeopardizing efficacy. However, Phase III trials are 
needed to confirm this approach.
Oxaliplatin, a new platinum compound, and irinotecan, 
a topoisomerase I inhibitor, both of which are active in col-
orectal cancer,25,26 have brought new hope in gastric cancer 
management. Oxaliplatin has been combined with epirubicin 
and 5-FU or capecitabine in a noninferiority randomized 
Phase III study (REAL-2) detailed in Table 2.27 On day 1 of 
every 3-week cycle, patients in all study groups received an 
intravenous bolus of epirubicin 50 mg/m², cisplatin 60 mg/m² 
was given intravenously with hydration in the ECF and 
epirubicin + cisplatin + capecitabine groups, and oxaliplatin 
130 mg/m² was administered intravenously over a 2-hour 
period in the epirubicin + oxaliplatin + 5-FU and epirubi-
cin + oxaliplatin + capecitabine groups. 5-FU 200 mg/m² and 
capecitabine 625 mg/m² twice daily were given throughout 
treatment. Median overall survival was in favor of the epiru-
bicin + oxaliplatin + capecitabine group (HR for death 0.80 
in the epirubicin + oxaliplatin + capecitabine group (95% CI: 
0.66–0.97; P = 0.02). Oxaliplatin was associated with less 
alopecia, and hematological and renal toxicity than cisplatin, 
whereas no difference was seen in terms of toxicity between 
5-FU and capecitabine. Based upon these results, oxaliplatin 
has a better toxicity profile than cisplatin without jeopardiz-
ing efficacy. Two   promising Phase I trials have been recently 
published combining docetaxel + oxaliplatin + capecitabine. 
Although the dose-limiting toxicity was different between 
the two studies, the combination might potentially become 
a valuable regimen in metastatic gastric cancer.28,29 Further 
evaluations using this combination are ongoing.
The advent of irinotecan has brought new opportunities 
for the management of metastatic gastric cancer by enabling 
use of combinations that do not contain a platinum com-
pound such as oxaliplatin or cisplatin.   Randomized Phase 
III   studies have recently been published in the literature. 
Dank et al compared a weekly regimen of   irinotecan + 5-FU 
(irinotecan 80 mg/m², folinic acid 500 mg/m², 5-FU 
2000 mg/m² for 6 weeks with 1 week rest) with the tradi-
tional cisplatin + 5-FU   combination. Although no survival 
advantage was seen in the   irinotecan + 5-FU group, this 
combination was not inferior to   cisplatin + 5-FU, with a 
comparable response rate, progression-free survival, and 
overall survival (Table 2).30 Recently presented data from the 
Federation Nationale des Centres de Lutte Contrele Cancer 
ACCORD07-FFCD 0307 trial showed encouraging results 
using FOLFIRI (irinotecan 180 mg/m² on day 1, folinic acid 
400 mg/m² day 1, bolus 5-FU 400 mg/m² on day 1 and con-
tinuous infusion of 5-FU 2400 mg/m² on days 1 and 2, every 
2 weeks) compared with e  pirubicin +   cisplatin + capecit-
abine (epirubicin 50 mg/m² on day 1 + cisplatin 60 mg/m² 
on day 1 + capecitabine 2000 mg/m² on days 2–15, every 
3 weeks). Both combinations showed the same results in 
terms of progression-free survival and overall survival, the 
toxicity profile being more favorable in the FOLFIRI arm.31 
A new parameter, firstly studied by Dank et al, ie, the time 
to therapeutic failure (corresponding to the time between 
randomization and progression, treatment discontinuation, 
recurrence, or death) was significantly improved in the FOL-
FIRI arm compared with epirubicin + cisplatin + capecit-
abine (5 months vs 4 months, HR: 0.77, CI: 95% 0.63–0.94; 
P = 0.008). These studies show that a noncisplatin-based 
treatment can have equivalent efficacy to a cisplatin-based 
combination in advanced gastric tumors, with fewer seri-
ous adverse events and treatment withdrawals because 
of toxicity. Therefore, dual therapy of irinotecan + 5-FU 
is a useful alternative for patients who cannot receive a 
cisplatin-based regimen and might become a new standard 
in first-line therapy for metastatic gastric cancer. The Japan 
Clinical Oncology Group 9912 trial randomized more than 
700 patients with advanced disease to either a cisplatin–
irinotecan doublet or single-agent treatment with infusional 
5-FU or the new oral   fluoropyrimidine, S-1 (Table 2). The 
cisplatin–irinotecan doublet achieved a superior response 
rate but failed to demonstrate any advantage in terms of Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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overall survival compared with the single-agent 5-FU treat-
ment, with a rather interesting 12.3 months of median over-
all survival (P = 0.055). However, in this patient population, 
the combined regimen was considerably more toxic than the 
monotherapy regimen and was associated with relatively 
high rates of toxicity-related withdrawal from treatment. 
The most common grade 3 toxicity was neutropenia (65% in 
the   cisplatin + irinotecan arm compared with approximately 
15% in the 5-FU and S-1 arms), with a 9% incidence of 
febrile neutropenia. Nonhematological toxicities were also 
markedly higher in the doublet than in the monotherapy 
arms.32 Therefore, this combination is not recommended 
as a first choice and must be used with caution.
Oral 5-FU has been developed in order to avoid the 
need for a central venous catheter which is inconvenient 
for patients and potentially associated with morbidity. 
  Capecitabine has been shown to be noninferior to infu-
sional 5-FU in doublet and triplet regimen studies.27,33 The 
doublet of capecitabine + cisplatin was compared with 
cisplatin + 5-FU in 316 chemo-naïve patients suffering 
from advanced gastric adenocarcinoma (Table 2). The 
median progression-free survival was identical between the 
groups (5.6 and 5.0 months for the capecitabine + cisplatin 
and cisplatin + 5-FU arms, respectively), thus meeting the 
primary objective of the study. The toxicity profile was 
similar between the groups, apart from hand-foot syndrome, 
which was higher in the capecitabine arm, as expected from 
other studies.34 Noninferiority in relation to survival with 
capecitabine vs 5-FU in triplet regimens for the treatment 
of patients with advanced esophagogastric cancer was 
also demonstrated in the REAL-2 trial (HR: 0.86, 95% 
CI: 0.80–0.99), as described in Table 2 and previously 
discussed.27
S-1, mainly developed in Japan, is a combination of three 
pharmacological components, ie, tegafur (a prodrug of 5-FU), 
5-chloro-2,4 dihydropyridine (a powerful inhibitor of dihy-
dropyrimidine dehydrogenase), and potassium oxonate (to 
protect against drug-induced diarrhea). The noninferiority of 
S-1 compared with infusional 5-FU has been demonstrated 
in the Japan Clinical Oncology Group 9912 trial and does 
not need further discussion.32
The recent SPIRITS trial showed superiority in terms 
of response rate, progression-free survival (6 vs 4 months, 
P , 0.0001), and overall survival (13 vs 11 months, P = 0.04) 
for the doublet regimen combining cisplatin (60 mg/m² day 8) 
and S-1 (40–60 mg depending on patient’s body surface area, 
given orally twice daily for 3 consecutive weeks) followed 
by a 2-week rest, compared with S-1 alone (same doses), 
leading Asian countries to consider this doublet as a standard 
for first-line therapy in metastatic gastric cancer35 (Table 2). 
Results from the FLAGS trial developed in Western coun-
tries comparing the traditional 5-FU + cisplatin (infusional 
5-FU 1000 mg/m²/24 hours for 120 hours and cisplatin at 
100 mg/m² intravenously on day 1, repeated every 28 days) 
with cisplatin + S-1 (S-1 50 mg/m² divided in two daily doses 
for 21 days and cisplatin at 75 mg/m² intravenously on day 1, 
repeated every 28 days) failed to demonstrate any survival 
advantage for the experimental group (Table 2). Response 
rates and progression-free survival, although not statistically 
significant, were in favor of the cisplatin + 5-FU arm.36 These 
discrepant results led physicians in Western countries not to 
recommend this combination. However, further analyses are 
needed to understand the huge differences observed between 
the studies.
Targeted therapies have emerged as a new hope in cancer 
management during recent years. Several drugs have been 
studied in gastric cancer, among which are angiogenesis and 
human epidermal growth factor receptor 1 and 2 (HER1 and 
HER2) inhibitors. The first to have demonstrated its efficacy in 
gastric malignancies is trastuzumab, a monoclonal antibody, 
targeting HER2. The ToGA trial (Table 2) in fact showed that 
adjunctive addition of trastuzumab (intravenously at a dose 
of 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg 
every 3 weeks) to cisplatin (intravenous infusion 80 mg/m2 
on day 1) and 5-FU   (intravenous infusion 800 mg/m2 per 
day on days 1–5 of each cycle) or capecitabine (1000 mg/
m² given orally twice a day for 14 days followed by a 1-week 
rest) was of benefit for patients with tumors showing overex-
pression of HER2 protein by immunohistochemistry or gene 
amplification by fluorescence in situ hybridization compared 
with chemotherapy alone.37 The combination reached for the 
first time in Western countries an overall survival above 1 
year (Table 3). Median progression-free survival and overall 
response rate was also ameliorated by trastuzumab (Table 3). 
Apart from diarrhea, the toxicity profile was identical in both 
groups, and particularly for cardiac adverse events, a specific 
toxicity observed with trastuzumab therapy, which was quite 
low with less than 1% of patients experiencing such problems. 
Based upon these results, the combination of trastuzumab and 
chemotherapy has become the standard of care in first-line 
therapy for patients suffering from HER2-positive gastric 
neoplasms.
The antiangiogenesis monoclonal antibody, bevacizumab, 
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has, on the other hand, failed to demonstrate any survival 
advantage in the randomized Phase III AVAGAST trial where 
the chemotherapy was identical to that used in the ToGA trial. 
However, median progression-free survival and response rate 
was significantly improved in the bevacizumab group (Table 3), 
with a favorable safety profile. Interestingly, variability in 
median overall survival were observed between geographical 
areas, and especially in the chemotherapy only groups, with a 
median overall survival of 8.6 and 6.8 months in the US and 
Europe, respectively.38 Mature and definitive data are awaited, 
especially in terms of second-line therapy used in both groups, 
which may explain the differences observed in survival.
Replacing cisplatin with oxaliplatin, El-Rayes et al 
assessed the combination of bevacizumab 7.5 mg/kg, doc-
etaxel 70 mg/m², and oxaliplatin 75 mg/m² on day 1, every 3 
weeks in a open-label Phase II study including 38 patients,39 
and the results are encouraging (Table 3). Sorafenib, a 
tyrosine kinase inhibitor targeting angiogenesis, has been 
recently studied in a Phase II study including 44 patients. 
Sorafenib 400 mg orally twice a day was combined with 
cisplatin 75 mg/m² on day 1 and docetaxel 75 mg/m² on day 1, 
and repeated every 21 days. A remarkable median overall 
survival of 13.5 months was reached, with a tolerable toxicity 
profile.40 This combination deserves further evaluation.
The Phase III EXPAND and REAL-3 trials are currently 
assessing the role of monoclonal antibodies vs the epidermal 
growth factor receptor in combination with chemotherapy. Cetux-
imab is combined with cisplatin and capecitabine in the EXPAND 
study, whereas panitumumab is combined with the English stan-
dard of epirubicin + oxaliplatin + capecitabine in the REAL-3 
trial. These studies are ongoing and results are pending.
Place of second-line therapy  
in metastatic gastric cancer
There is no huge difference in terms of response rate when 
comparing patients with colorectal cancer and those with 
gastric cancer. However, corresponding improvement in 
median overall survival has not yet been reached by the 
  combination therapies currently available. This lack of 
progress in improving overall survival is partly due to dif-
ferences in the surgical management of metastatic disease, 
and also related to the limited efficacy of second-line and 
third-line treatments for advanced disease, given that, 
unlike patients with colorectal cancer, patients suffering 
from metastatic gastric malignancies are usually not able to 
receive second-line or third-line chemotherapy. Currently 
available data for second-line and third-line therapy are 
emerging from Phase II studies, although one Phase III 
study has assessed the role of marimastat in first-line and 
second-line therapy in patients   suffering from metastatic 
gastric tumors. A significant survival benefit was identified 
at study completion in the subgroup of patients who had 
received prior chemotherapy (HR: 1.53, 95% CI: 1.00–
0.34; P = 0.045). Furthermore, marimastat did not worsen 
the prognosis when used as first-line therapy. Median 
progression-free survival was also significantly longer for 
patients receiving marimastat compared with placebo (HR: 
1.32, 95% CI: 1.07–1.63; P = 0.009).41 Several Phase II 
studies assessing different chemotherapeutic regimens 
in a small number of patients have been published.42–49 
Response rates are between 11% and 32%, with median 
time to progression of around 3 months and a median over-
all survival reaching 11.7 months in a study of sunitinib, 
an oral, multitargeted tyrosine kinase inhibitor, as single-
agent therapy in 42 evaluable gastric cancer patients with 
stage IV disease who had failed first-line chemotherapy. 
The toxicity profile was also favorable.49 Therefore, suni-
tinib deserves our attention and should be further assessed 
in clinical trials, either alone or in combination with other 
chemotherapeutic agents.
Conclusion
Major advances have been made during the last two decades 
in the management of gastric cancer, not only for metastatic 
disease but also for resectable disease. The multidisciplinary 
approach involving the surgeon as well as the radiation thera-
Table 3 Targeted therapies in metastatic gastric cancer: current results
Phase n Regimen RR (%) PFS (m) OS (m)
Bang et al37 iii 298/296 Tr-C-5-FU/C-5FU 47/35 (P = 0.0017) 6.7/5.5 (P = 0.0002) 13.8/11.1 (P = 0.0046)
Kang et al38 iii 387/387 B-C-5-FU/C-5FU 38/29.5 (P = 0.0121) 6.7/5.3 (P = 0.0037) 12.1/10.1 (NS)
el-Rayes et al39 ii 38 B-O-D 42 6.6 11.1
Sun et al40 ii 44 Sor-C-D 41 5.8 13.5
Abbreviations: n, number of patients; RR, response rate; TTF, time to treatment failure; PFS, progression free survival; OS, overall survival; Tr, trastuzumab; C, cisplatin; 
5-FU, 5-fluorouracil; B, bevacizumab; O, oxaliplatin; D, docetaxel, Sor, sorafenib.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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pist and oncologist allows clinicians to improve survival in 
patients with locally advanced disease amenable to surgery.
Perioperative chemotherapy and adjuvant chemoradia-
tion are the two options confirmed in the literature to improve 
the surgical outcome, the latter being reserved for patients 
not treated by chemotherapy before surgery, and having 
a high risk of tumor recurrence, based upon pathological 
findings.
In the case of palliative treatment, the endpoint is to slow 
tumor growth as far as possible. The currently available first-
line treatments for advanced gastric cancer offer a clear sur-
vival benefit to patients compared with best supportive care 
alone. Apart from the doublet of cisplatin + S-1, triple regi-
mens, such as docetaxel +   cisplatin + 5-FU,   epirubicin + oxali-
platin + capecitabine, and trastuzumab + cisplatin + 5-FU, 
have demonstrated benefit compared with other regimens. 
Although no direct comparative data suggest which of these 
is the most effective, the   trastuzumab +   cisplatin + 5-FU 
combination seems to be the best regimen for patients 
expressing HER2, while   docetaxel + cisplatin + 5-FU is 
recommended for HER2-negative patients. Because doc-
etaxel + cisplatin + 5-FU is an intensive combination, some 
consideration must be given to the use of docetaxel with 
less intensive regimens (such as with oral fluoropyrimidines 
or by using weekly schedules). However, recommendations 
for therapy should be individualized, based on the patient’s 
performance status and comorbidities.
Many oncologists consider all gastric tumors as different 
entities, either based upon histology or tumor location, and 
even by molecular markers. It is unclear why certain tumors 
grow differently when they are similar in terms of   histology 
and location. Better comprehension of the   molecular 
mechanisms responsible for the genesis of gastric cancer is 
fundamental to improve tumor management. Translational 
research has already brought hope in gastric cancer, allowing 
physicians to select tumors responsive to targeted therapies. 
Future research will surely help clinicians to select and adapt 
these treatments to individual patients.
However, it is unclear why tumors benefit differently from 
chemotherapy with regard to their histology or location. Since 
the majority of the published studies have included patients 
with tumors located at different sites, with different tumor stage 
and histology, rendering the populations quite   heterogeneous. 
Future trials might perhaps select patient populations better, 
taking into account the different parameters cited above, as 
well as biomarkers already utilized in other malignancies, 
such as breast cancer.
The future of gastric cancer management should focus 
not only on the best chemotherapeutic regimen, but also on 
improving early response evaluation in order to avoid long, 
toxic, and ineffective treatments, and to find prognostic 
biomarkers which allow physicians to tailor treatment to the 
individual. The role of metabolic assessment using positron 
emission tomography has been proven   effective in   predicting 
responders to chemotherapy in terms of histologic tumor 
regression and patient survival in patients treated with preop-
erative chemotherapy followed by   surgery.50 A recent review 
of the literature showed that positron emission tomography 
can contribute to the selection of a more appropriate treatment 
modality by better detecting distant metastases and treatment 
response than conventional imaging techniques.51
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